infarction ischemia reperfusion injury
Conditions
Interventions
10 Volunteers will be randomised to receive in a cross-over design a two and a
half day (5 capsules) treatment with dipyridamole (Persantin retard
200 mg
twice daily) followed by 10 minutes of ischemic isometric muscle contraction of
the non-dominant forearm and upon reperfusion infusion of radiolabeled Annexin
A5 (Annexin scintigraphy) and A
Sponsors
Universitair Medisch Centrum Sint Radboud
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: male age 18-50 years
Exclusion criteria
Exclusion criteria: -cardiovascular disease -hypertension (systole > 140 mmHg, diastole > 90 mmHg) -hypercholesterolemia (fasting total cholesterol > 5.5 mmol/l or not fasting total cholesterol > 6.5mmol/L) -diabetes mellitus (fasting glucose > 7.0 mmol/L or random glucose > 11.0 mmol/L) -asthma (recurrent episodes of dyspnea and wheezing, or usage of prescribed inhalation medication: i.e. corticosteroids or B2-agonists) -participation in any clinical drug trial during the last 60 days prior to this study. -administration of any radioactivity for research purposes during the last 5 years prior to this study. -concomittant medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage difference in radioactivity (counts/pixel) between experimental and control thenar muscle at 60 and 240 minutes after reperfusion. | — |
Secondary
| Measure | Time frame |
|---|---|
| nvt | — |
Countries
Netherlands
Outcome results
None listed